Immuron Ltd ADR (IMRN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Immuron Ltd ADR stock (IMRN) is currently trading at $0.81. Immuron Ltd ADR PS ratio (Price-to-Sales) is 0.96. Analyst consensus price target for IMRN is $3.89. WallStSmart rates IMRN as Sell.
- IMRN PE ratio analysis and historical PE chart
- IMRN PS ratio (Price-to-Sales) history and trend
- IMRN intrinsic value — DCF, Graham Number, EPV models
- IMRN stock price prediction 2025 2026 2027 2028 2029 2030
- IMRN fair value vs current price
- IMRN insider transactions and insider buying
- Is IMRN undervalued or overvalued?
- Immuron Ltd ADR financial analysis — revenue, earnings, cash flow
- IMRN Piotroski F-Score and Altman Z-Score
- IMRN analyst price target and Smart Rating
Immuron Ltd ADR
📊 No data available
Try selecting a different time range
Smart Analysis
Immuron Ltd ADR (IMRN) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Immuron Ltd ADR (IMRN) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Immuron Ltd ADR (IMRN) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Revenue growing slowly at 4.80% annually
Very low institutional interest at 2.01%
Micro-cap company with very limited liquidity and high volatility
Immuron Ltd ADR (IMRN) Detailed Analysis Report
Overall Assessment
This company scores 31/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book. Valuation metrics including Price/Sales (0.96), Price/Book (0.63) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Growth concerns include Revenue Growth at 4.80%, which may limit upside. Profitability pressure is visible in Return on Equity at -39.70%, Operating Margin at -47.20%, Profit Margin at -62.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -39.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 4.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IMRN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IMRN's Price-to-Sales ratio of 0.96x trades at a deep discount to its historical average of 36.75x (3th percentile). The current valuation is 100% below its historical high of 268.93x set in Aug 2021, and 10% above its historical low of 0.87x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~3.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Immuron Ltd ADR (IMRN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Immuron Ltd ADR is in a turnaround phase, with management focused on restoring profitability. Revenue reached 7M with 5% growth year-over-year. The company is currently unprofitable, posting a -62.1% profit margin.
Key Findings
Spending 15% of revenue (1M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -62.1% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Immuron Ltd ADR.
Bottom Line
Immuron Ltd ADR is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Immuron Ltd ADR(IMRN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immunomodulated diseases in Australia, the United States and internationally. The company is headquartered in Carlton, Australia.